Answers are grounded in this paper and cite their sources.
Preclinical evaluation shows improved outcomes in engineered PSMA-targeted radioligands for prostate cancer, suggesting potential benefits for patients.
To improve the theranostic efficacy of PSMA-targeted radiopharmaceuticals on patients with medium-to-low PSMA expression, we radiolabeled a series of novel designed PSMA-targeting dimer agents to improve tumor imaging and treatment outcomes under challenging conditions. All agents were successfully radiolabeled with 68 Ga in moderate decay-corrected labeling yield and high radiochemical purity. Among them, [ 68 Ga]Ga-TVS-PSMA- 1 exhibited high tumor uptake in both LNCaP and 22RV1 models. [ 177 Lu]Lu-TVS-PSMA- 1 demonstrated significantly improved treatment efficacy with a lower dose and good safety profile compared with [ 177 Lu]Lu-PSMA-617. A first-in-human [ 68 Ga]Ga-TVS-PSMA- 1 PET/CT scan was performed in a 66-year-old male prostate cancer patient. Two metastatic lesions in the lumbar vertebrae were clearly visualized, and the primary tumor exhibited an SUVmax of 30.3. The [ 68 Ga]Ga-TVS-PSMA- 1 showed lower salivary gland uptake compared with previously reported values for [ 68 Ga]Ga-PSMA-11; however, confirmation in larger patient cohorts is required. This study demonstrates that the dimer agent TVS-PSMA- 1 holds great potential as a next-generation theranostic agent for prostate cancer.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: